DiaMedica Therapeutics Inc..
DMAC.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, particularly acute ischemic stroke (AIS) and chronic kidney disease (CKD). Their primary drug candidate, DM199, is a recombinant form of human tissue kallikrei...Show More
Better Health for All
0
No relevant data was found in the provided article to assess DMAC.US against the 'Better Health for All' ethical value.
1
The article indicated that no data was accessible from the given link.
2
Fair Money & Economic Opportunity
0
DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders.
1
Its core business is not in financial services, and it does not offer lending, deposit, or other financial products to consumers.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to its operations, as per the rubric's definition for companies outside the financial sector.
Fair Pay & Worker Respect
20
In 2024, DiaMedica Therapeutics Inc.'s CEO, Rick Pauls, received a total compensation of $1,550,985, resulting in a CEO-to-median U.S. worker pay ratio of 31:1.
1
Fair Trade & Ethical Sourcing
0
No relevant data or specific metrics pertaining to Fair Trade & Ethical Sourcing for DiaMedica Therapeutics Inc. (DMAC.US) could be extracted from the provided articles.
1
All articles explicitly stated that no data was accessible or found for the requested categories.
2
Honest & Fair Business
-20
DiaMedica Therapeutics Inc. has a comprehensive whistleblower policy applicable to all directors, officers, and employees, allowing for confidential and anonymous reporting of concerns regarding accounting or auditing matters to a supervisor, the Chief Financial Officer, or the Audit Committee Chair, and explicitly prohibiting retaliation against good-faith reporters.
1
The company's Board of Directors has determined that seven out of eight current directors are independent under Nasdaq Listing Rules, representing 87.5% of the board.
2
The company has a Code of Business Conduct and Ethics, adopted in October 2018, which includes a section on the Foreign Corrupt Practices Act (FCPA) prohibiting bribery and kickbacks to foreign officials.
3
However, the policy's training frequency and effectiveness metrics are not specified. Baker Tilly US, LLP serves as the independent registered public accounting firm, appointed in April 2018, and the Audit Committee has sole authority to appoint, oversee, and terminate their engagement, pre-approving all audit and permissible non-audit services.
4
The Compensation Committee also engaged Alpine Rewards, LLC as an independent compensation consultant.
5
Kind to Animals
-10
DiaMedica Therapeutics Inc. relies on animal testing for product safety and efficacy, having completed a placental transfer study in 30 pregnant rats and 24 pups.
1
The company is also conducting a 10-day modified embryo-fetal development and pre- and postnatal development study in a rabbit model, which was required by the FDA.
2
There is no evidence that the company employs non-animal testing methods for product safety and efficacy. The company's policy prohibits discretionary testing, but legal mandates still override alternatives. However, its lead drug candidate, DM199, is produced using recombinant DNA technology, eliminating the need for extracted human or animal tissue sources, such as porcine pancreas, which were historically used for KLK1.
3
No War, No Weapons
0
No evidence was found in the provided articles to assess DiaMedica Therapeutics Inc. against any of the KPIs for the 'No War, No Weapons' ethical value. The articles primarily contain financial information and company announcements unrelated to arms manufacturing, military contracts, conflict facilitation, or peacebuilding initiatives.
Planet-Friendly Business
0
No specific, concrete data points were provided in the articles for any of the Planet-Friendly Business KPIs.
1
The articles primarily focus on financial performance, clinical trial progress, and general business operations, without disclosing environmental impact metrics such as emissions, renewable energy use, water consumption, waste diversion, or climate targets and initiatives.
2
Therefore, no KPIs can be scored based on the provided evidence.
Respect for Cultures & Communities
0
No evidence available to assess DiaMedica Therapeutics Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
-30
The company reports no documented incidents of unauthorized data use.
1
It provides ongoing cybersecurity awareness training to employees, covering topics such as social engineering and email fraud.
2
The company also utilizes advanced technologies for continuous monitoring and engages third-party experts for vulnerability evaluation and testing, in addition to conducting periodic testing of cybersecurity controls and procedures.
3
However, the company's privacy policy indicates minimal user control over personal data, with users only able to refuse cookies, which may affect access to certain features.
4
Furthermore, the company's privacy policy does not detail data minimization practices or retention schedules, suggesting a lack of specific efforts in this area.
5
While the company discusses compliance with various regulations, including FDA, it does not provide specific details on GDPR compliance, which is relevant given its involvement in clinical trials.
6
Zero Waste & Sustainable Products
0
No specific, concrete data points or facts were found in the provided articles regarding DiaMedica Therapeutics Inc.'s waste diversion rate, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education programs.
1
The articles only indicate the availability of annual reports and SEC filings, but do not contain the actual data required for scoring these KPIs.